EGFR and head and neck squamous cell carcinoma: In 2011, the Food and Drug Administration (FDA) approved cetuximab, a monoclonal antibody against the epidermal growth factor receptor (EGFR), as a treatment for recurrent and metastatic HNSCC (R/M HNSCC) [2,28,29].